OptumRx and CVS Pharmacy Partner to Expand Consumer Choice, Reduce Costs and Improve Health Outcomes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
UBS Raises Price Target on UnitedHealth Group (UNH) Following Investor Day
November 30, 2016 9:49 AM ESTUBS reiterated a Buy rating on UnitedHealth Group (NYSE: UNH), and raised the price target to $193.00 (from $180.00), following the company's investor day. UNH expects its Medicare Advantage enrollment to grow by 700-800K lives in 2017, a 19-22% Y/Y increase. UBS raised 2016 EPS estimates to $9.45 and... More
Leerink Partners Raises Price Target on UnitedHealth Group (UNH) to $195; Reiterates Outperform
November 30, 2016 7:46 AM ESTLeerink Partners reiterated an Outperform rating on UnitedHealth Group (NYSE: UNH), and raised the price target to $195.00 (from $185.00), following a company update. EPS guidance of $9.30 - $9.60 came in better than the Street expectation of $9.16. The EPS upside is driven by better than expected top-line growth in MA, and Optum as well as the ObamaCare tax holiday.
Analyst Ana Gupte, commented, "We remain bullish on UNH (OP) and reiterate our top pick status on the name while raising estimates and PT to $195. In addition to surprising meaningfully to the upside on 2017 guidance,... More
